Home - VHIO

MYC: from undruggable target to the first cancer clinical trials

The MYC oncogene is deregulated in approximately 70% of human cancers and is associated with aggressive disease and cancer drug resistance,...

Presented at ASCO GU 2025, results of the phase 3 TALAPRO-2 trial support a new standard-of-care for metastatic castration-resistant prostate cancer

Results of the multi-center, international phase 3 TALAPRO-2 trial show that the combination of PARP inhibitor talazoparib plus anti-androgen enzalutamide...

VHIO Joins JANE-2, a Comprehensive EU Initiative to Advance Cancer Care Through Seven New EU Networks

The second Joint Action of the EU on Networks of Expertise on Cancer (JANE-2) officially launched on January 28-29, 2025,...

The MYC oncogene is deregulated in approximately 70% of human cancers and is associated with aggressive disease and cancer drug resistance,...

MYC: from undruggable target to the first cancer clinical trials

Results of the multi-center, international phase 3 TALAPRO-2 trial show that the combination of PARP inhibitor talazoparib plus anti-androgen enzalutamide...

Presented at ASCO GU 2025, results of the phase 3 TALAPRO-2 trial support a new standard-of-care for metastatic castration-resistant prostate cancer

The second Joint Action of the EU on Networks of Expertise on Cancer (JANE-2) officially launched on January 28-29, 2025,...

VHIO Joins JANE-2, a Comprehensive EU Initiative to Advance Cancer Care Through Seven New EU Networks

Latest News

On February 26, the second edition of the Computational Oncology Master Thesis Awards took place, organized by VHIO with the aim of...

27 February 2025

VHIO presents the 2nd edition of the Computational Oncology Master Thesis Awards

On February 26, the second edition of the Computational Oncology Master Thesis Awards took place, organized by VHIO with the aim of...

The MYC oncogene is deregulated in approximately 70% of human cancers and is associated with aggressive disease and cancer drug resistance,...

20 February 2025

MYC: from undruggable target to the first cancer clinical trials

The MYC oncogene is deregulated in approximately 70% of human cancers and is associated with aggressive disease and cancer drug resistance,...

Results of the multi-center, international phase 3 TALAPRO-2 trial show that the combination of PARP inhibitor talazoparib plus anti-androgen enzalutamide...

13 February 2025

Presented at ASCO GU 2025, results of the phase 3 TALAPRO-2 trial support a new standard-of-care for metastatic castration-resistant prostate cancer

Results of the multi-center, international phase 3 TALAPRO-2 trial show that the combination of PARP inhibitor talazoparib plus anti-androgen enzalutamide...

The second Joint Action of the EU on Networks of Expertise on Cancer (JANE-2) officially launched on January 28-29, 2025,...

13 February 2025

VHIO Joins JANE-2, a Comprehensive EU Initiative to Advance Cancer Care Through Seven New EU Networks

The second Joint Action of the EU on Networks of Expertise on Cancer (JANE-2) officially launched on January 28-29, 2025,...

VIEW MORE NEWS

PRINCIPAL RESEARCHERS

Cristina Saura

Breast Cancer & Melanoma Group

The main area of expertise of the Breast Cancer Group is clinical research focused on drug development and associated translational…

Elena Garralda

Early Clinical Drug Development Group

We focus on proof-of-concept and proof-of-mechanism trials with targeted therapies, with particular emphasis on cell signaling, cancer stem cells, and…

Teresa Macarulla

Gastrointestinal and Endocrine Tumors Group

Our group continues to play an essential role in developing molecular therapies against GI malignancies. We make important contributions to…

Alena Gros

Tumor Immunology and Immunotherapy Group

Our group focuses on better understanding the naturally occurring T-cell response to cancer and establishing ways to exploit these antitumor…

Events

Thursday 13 November 25 - 09:00 AM 2nd VHIO-BBVA Foundation Symposium on Cell-Based Therapies in Oncology

VIEW DETAIL